Lupin is a renowned pharma player having a wide range of quality, affordable generic and branded formulations and APIs. The company, which was named after the Lupin flower, commenced its business in 1968.
It has world class manufacturing facilities across India and Japan that have played a critical role in enabling the company realise its global aspirations. Benchmarked to international standards, Lupin’s facilities are approved by international regulatory agencies such as US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and the MCC South Africa.
The company first gained recognition when it became one of the world's largest manufacturers of Tuberculosis (TB) drugs. Today, it has significant market share in the cardiovascular, diabetology, asthma, paediatrics, CNS, anti-infectives and NSAIDs therapy segments.
Advanced market formulations comprised nearly 52 per cent of Lupin’s revenues in FY 12. Its drugs and products reached over 100 countries in the world.
The company has emerged as the fifth largest and among the fastest-growing companies in the US. The company's consolidated revenues and profit after tax were Rs 94,616 million (US$ 1.55 billion) and Rs 13,142 million (US$ 216.05 million), respectively, for FY 2012–13.
Lupin: On a High Growth Path
|2014||Acquires Nanomi B.V. – enters complex injectables space|
|2013||Inaugurates new plant at Nagpur|
|2011||Enters into joint development agreement with Medicis|
|2007||Receives ‘Best new manufacturer of the year’ award from Amerisource Bergen|
|2002||Crosses 100 mark in patent filings|
Updated: April, 2014